HOTH Hoth Therapeutics, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
19:34
Jan 22
Jan 22
HOTH undervalued on trial data, EU approval
The author argues HOTH Therapeutics is undervalued at ~$1.05 despite very good data from its CLEER-001 trial and a high reported success rate in trials. They cite last week's EU regulatory green light as a catalyst and believe the market is sleeping on the stock, expecting a massive run soon. The main stated risk is implicit market underappreciation, though no explicit risk is named.
HIGH
About HOTH Investor Commentary
Across the available history and selected sources, Buzzberg tracks HOTH (Hoth Therapeutics, Inc.) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: u/Apprehensive-Ice5690.